These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 7676276)

  • 21. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A; Schulman S; Varon D; Martinowitz U; Kenet G; Gitel S; Inbal A
    Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
    Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [An inhibitor in the Willebrand-Jürgens syndrome and its effect on the factor VIII molecule properties].
    Lenk H; Weissbach G; Domula M
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1978; 105(6):826-34. PubMed ID: 85595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Haemostatic management of intraoral bleeding in patients with von Willebrand disease.
    Morimoto Y; Yoshioka A; Sugimoto M; Imai Y; Kirita T
    Oral Dis; 2005 Jul; 11(4):243-8. PubMed ID: 15984956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E; Windyga J;
    Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acquired type 3-like von Willebrand syndrome preceded full-blown systemic lupus erythematosus.
    Niiya M; Niiya K; Takazawa Y; Hayashi Y; Tanio Y; Kushiro M; Tanimizu M; Hasegawa H; Tanimoto M
    Blood Coagul Fibrinolysis; 2002 Jun; 13(4):361-5. PubMed ID: 12032403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Non-hemophilic patient with inhibitor against factor VIII produced after the second delivery].
    Akahori M; Yamane T; Hino M; Ohta K; Takubo T; Samori T; Tatsumi N
    Rinsho Byori; 1999 Sep; 47(9):891-5. PubMed ID: 10518429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of the pharmacokinetics of two von Willebrand factor concentrates [Biostate and AHF (High Purity)] in people with von Willebrand disorder. A randomised cross-over, multi-centre study.
    Favaloro EJ; Lloyd J; Rowell J; Baker R; Rickard K; Kershaw G; Street A; Scarff K; Barrese G; Maher D; McLachlan AJ
    Thromb Haemost; 2007 Jun; 97(6):922-30. PubMed ID: 17549293
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Laboratory testing for von Willebrand disease: contribution of multimer analysis to diagnosis and classification.
    Budde U; Pieconka A; Will K; Schneppenheim R
    Semin Thromb Hemost; 2006 Jul; 32(5):514-21. PubMed ID: 16862525
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acquired von Willebrand's syndrome during autoimmune disorder.
    Pizzuto J; Ambriz R; de la Paz Reyna M; Monrroy LM; Morales MR; Aviles A; Conte G; Enriquez R
    Thromb Haemost; 1980 Feb; 42(5):1523-8. PubMed ID: 6966081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acquired von Willebrand syndrome: features and management.
    Mohri H
    Am J Hematol; 2006 Aug; 81(8):616-23. PubMed ID: 16823821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Examination of the inhibitor to factor VIII in non-haemophilic patient].
    Suetomo M; Suehisa E; Nishimura K; Toyokawa M; Toku M; Fushimi R; Amino N; Miyai K; Izumi M; Ohtsuka A
    Rinsho Byori; 1991 Jul; 39(7):748-52. PubMed ID: 1920868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mapping and functional studies of two alloantibodies developed in patients with type 3 von Willebrand disease.
    Tout H; Obert B; Houllier A; Fressinaud E; Rothschild C; Meyer D; Girma JP
    Thromb Haemost; 2000 Feb; 83(2):274-81. PubMed ID: 10739386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Standardisation of factor VIII and von Willebrand factor in plasma: calibration of the 4th International Standard (97/586).
    Hubbard AR; Rigsby P; Barrowcliffe TW
    Thromb Haemost; 2001 Apr; 85(4):634-8. PubMed ID: 11341497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acquired von Willebrand's disease following bone marrow transplantation.
    Lazarchick J; Green C
    Ann Clin Lab Sci; 1994; 24(3):211-5. PubMed ID: 8048792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Management of patients with Type 2B von Willebrand's disease during delivery and puerperium].
    Güth U; Tsakiris DA; Reber A; Holzgreve W; Hösli I
    Z Geburtshilfe Neonatol; 2002; 206(4):151-5. PubMed ID: 12198592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [4 cases of acquired Willebrand factor deficiency associated with monoclonal dysglobulinemia].
    Horellou MH; Baumelou E; Sitbon N; Marie JP; Conard J; De Carbonnières C; Gorin NC; Zittoun R; Samama M
    Ann Med Interne (Paris); 1983; 134(8):707-12. PubMed ID: 6421219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.